Haemodynamic effects of chronic tetramethylpyrazine administration on portal hypertensive rats

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 9, 1999, Pages 1027-1031

  Chang, Fang Chi ^a   Huang, Yi Tsau ^b   Hong, Chuang Ye ^b   Lin, Jaung Geng ^c   Chen, Ke Ji ^a  

^a XIYUAN HOSPITAL   (China)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cirrhosis; Haemodynamics; Portal hypertension; Tetramethylpyrazine

Indexed keywords

ALKALOID; TETRAMETHYLPYRAZINE;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; BILE DUCT LIGATION; CHINESE HERB; CONTROLLED STUDY; HEART INDEX; HEART RATE; HEMODYNAMICS; INTRAGASTRIC DRUG ADMINISTRATION; LIVER CIRRHOSIS; MEAN ARTERIAL PRESSURE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; VASCULAR RESISTANCE; VEIN LIGATION;

EID: 0032707545     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199909000-00013     Document Type: Article

References (28)

1. Beijing Research Institute of the Pharmaceutical Industry. Research on the active ingredients of Ligusticum wallichii. I. Extraction, separation, and chemical characterization. Chin Med J 1977; 7:420-421.
2. Ojewole JAO. Effects of tetramethylpyrazine on isolated atria of the guineapig. Planta Med 1981; 42:223-228.
3. Kosuqe T, Kamiya H. Discovery of a pyrazine in a natural product: tetramethylpyrazine from culture of a strain of Bacillus subtilis. Nature 1962; 193:776.
4. Beijing Research Institute of the Pharmaceutical Industry. Research on the active ingredients of Ligusticum wallichii. III. Clinical (218 cases) use of tetramethylpyrazine in the treatment of hypoxemic cerebral vascular diseases. Chin Med J 1977; 7:467-469.
5. Peng W, Duan SF. Effects of ligustrazine controlled release capsule on pulmonary hemodynamics in chronic pulmonary heart disease. Chin J Tuberc Resp Dis 1992; 15:217-219.
6. Wang ZL, Kwan CY, Ohta A, Chen MC. Inhibitory effects of tetramethyl and tetraethyl derivatives of pyrazine on dog saphenous vein. Can J Physiol Pharmacol 1991; 69:1184-1189.
7. Pang PKT, Shan JJ, Chiu KW. Tetramethylpyrazine, a calcium antagonist. Planta Med 1996; 62:431-435.
8. Wu C-C, Chiou W-F, Yen M-H. A possible mechanism of action of tetramethylpyrazine on vascular smooth muscle in rat aorta. Eur J Pharmacol 1989; 169:189-195.
9. Peng W, Hucks D, Priest RM, Kan YM, Ward JPT. Ligustrazine-induced endothelium-dependent relaxation in pulmonary arteries via an NO-mediated and exogenous L-arginine-dependent mechanism. Br J Pharmacol 1996; 119:1063-1071.
10. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22:332-354.
11. Reichen J. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension. Hepatology 1990; 11:1066-1078.
12. Lebrec D. Pharmacological treatment of portal hypertension: hemodynamic effects and prevention of bleeding. Pharmacol Ther 1994; 61:65-107.
13. Reichen J, Hirlinger A, Ha HR, Sagesser S. Chronic verapamil administration lowers portal pressure and improves hepatic function in rats with liver cirrhosis. J Hepatol 1986; 3:49-58.
14. Reichen J, Le M. Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of liver. J Clin Invest 1986; 78:448-455.
15. Chang F-C, Chen K-J, Lin J-G, Hong C-Y, Huang Y-T. Effects of tetramethylpyrazine on portal hypertensive rats. J Pharm Pharmacol 1998; 50:881-884.
16. Chojkier M, Groszmann RJ. Measurement of portal systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981; 240:G371-G375.
17. Huang Y-T, Wang G-F, Yang MCM, Chang S-P, Lin H-C, Hong C-Y. Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement. J Pharmacol Exp Ther 1996; 278:535-541.
18. Kountouras J, Bitting BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984; 65:305-311.
19. Albillos A, Colombato LA, Groszmann RJ. Vasodilatation and sodium retention in prehepatic portal hypertension. Gastroenterology 1992; 102:931-935.
20. Huang Y-T, Lin H-C, Tsai J-F, Hou M-C, Hong C-Y. Chronic administration of propranolol improves vascular contractile responsiveness in portal hypertensive rats. Eur J Clin Invest 1997; 27:550-555.
21. Colombato LA, Robin M, Pomier-Layrargues G, Huet P-M. Animal models of portal hypertension. In: Portal Hypertension. Holstege A, Hahn EG, Scholmerich J (editors). London: Kluwer Academic Publishers; 1995. pp. 3-14.
22. Lin H-C, Wu H-L, Huang Y-T, Hou M-C, Lee S-D, Hong C-Y. Haemodynamic effects of 8-day octreotide and prazosin treatment in portal hypertensive rats. Eur J Clin Invest 1997; 28:622-628.
23. Huang Y-T, Cheng Y-R, Lin H-C, Chen C-F, Hong C-Y. Haemodynamic effects of chronic tetrandrine treatment in portal hypertensive rats. J Gastroenterol Hepatol 1997; 12:585-589.
24. Huang Y-T, Liu T-B, Cheng Y-R, Lin H-C, Chen C-F, Chen S-M. Chronic portal hypertensive effects of tetrandrine and verapamil on portal hypertensive rats. Asia Pac J Pharmacol 1997; 12:31-35.
25. Liu T-B, Lin H-C, Huang Y-T, Sun C-M, Hong C-Y. Portal hypotensive effects of tetrandrine and verapamil on portal hypertensive rats. J Pharm Pharmacol 1997; 49:85-88.
26. Dai X-Z, Bache RJ. Coronary and systemic hemodynamic effects of tetramethylpyrazine in the dog. J Cardiovasc Pharmacol 1985; 7:841-849.
27. + channels. Life Sci 1995; 56:295-306.
28. Henriksen J, Ring-Larsen H. Renal effects of drugs used in the treatment of portal hypertension. Hepatology 1993; 18:688-695.